OncoMatch/Breast Cancer/PGR (PR)
Breast CancerPGR (PR) Clinical Trials
Progesterone receptor (PR) expression is assessed alongside ER as part of hormone receptor testing and influences prognosis and treatment planning. PR positivity typically co-occurs with ER positivity and correlates with better endocrine therapy response. Trials enrolling HR+ patients (ER+ and/or PR+) include CDK4/6 inhibitor combinations, PI3K/AKT pathway agents, antibody-drug conjugates, and endocrine backbone strategies.
Top recruiting PGR (PR) Breast Cancer trials
Ranked by phase and US site count. See all 143 trials matched to your profile →
De-Escalation of Breast Radiation Trial for Hormone Sensitive, HER-2 Negative, Oncotype Recurrence Score Less Than or Equal to 18 Breast Cancer (DEBRA)
NRG Oncology
Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/AFT-65 OptimICE-RD/GBG 119/NSABP B-63)
Gilead Sciences
Phase IIIb Study of Ribociclib + ET in Early Breast Cancer
Novartis Pharmaceuticals
Neoadjuvant Endocrine Therapy Versus Chemotherapy in Premenopausal Patients With ER+ & HER2- Breast Cancer
Peking University
Personalizing the Use of Pembrolizumab for Patients Who Have a Strong Response in Early Triple Negative Breast Cancer
UNICANCER
Safety and Efficacy Analysis of an Antibody Associated With a Chemotherapy for Patients With a Triple Negative Metastatic Breast Cancer
UNICANCER
Browse other molecular targets with active Breast Cancer trials.